"Our goal is to develop drugs that will have positive effects on healthcare outcomes."
$245 billion is spent annually to treat type 2 diabetes in the U.S. Globally, nearly 50 percent of those diagnosed with diabetes live in just 3 countries (China, India, U.S.). Yet, diabetes can and should be prevented.
A mitochondrial protein complex has been identified by researchers at Metabolic Solutions Development Company (MSDC) through which anti-diabetic drugs exert their insulin sensitizing effects when used to treat patients diagnosed with type 2 diabetes. The mitochondrial protein complex is being referred to as the mitochondrial Target of Thiazolidinediones (TZDs), or mTOT™.
Alzheimer’s disease has been characterized as “type 3 diabetes.” Insulin sensitizers may play a role in treating Alzheimer’s disease and MSDC has developed a new insulin sensitizer that may prevent cognitive decline in people with Alzheimer’s-related dementia.
mediData presented to date suggest that the mTOT protein complex functions as a molecular "sensor switch" connecting mitochondrial metabolism to important cellular activities perturbed in age-related metabolic diseases such as type 2 diabetes, including insulin sensitivity. MSDC's novel pharmaceutical agents selectively bind and modulate proteins in the mTOT complex, effecting pyruvate utilization and resulting in improved insulin action, lipid oxidation, preservation of beta cell function, and generation of brown fat.a?
A study published online in the Journal of Biological Chemistry, titled “Insulin Resistance and Metabolic Derangements in Obese Mice are Ameliorated by a Novel Peroxisome Proliferator-Activated Receptor-sparing Thiazolidinedione”, showed a new drug to treat diabetes being developed by Metabolic Solutions Development Company (MSDC), MSDC-0602, improved insulin resistance and inflammation in obese mice. These findings suggest that MSDC-0602, a novel anti-diabetic drug which is in Phase 2 clinical trials, may constitute the first in a class of next generation insulin sensitizers that appear to work through a new biochemical mechanism to treat insulin resistance and type 2 diabetes.
In a recently completed Phase 2b study, MSDC-0160, a novel once-a-day oral insulin sensitizer and a prototype first in a new class of therapeutic agents called mTOT Modulators™, which are being developed by researchers at Metabolic Solutions Development Company (MSDC), met the primary endpoint of significantly reducing fasting plasma glucose (FPG) in patients diagnosed with type 2 diabetes, and significantly reduced hemoglobin A1c (HbA1c).
Following publication of research findings in the journal Science Translational Medicine, Patrik Brundin, MD, PhD, director of Van Andel Research Institute’s Center for Neurodegenerative Science, and chairman of The Cure Parkinson’s Trust’s Linked Clinical Trials Committee, discusses MSDC-0160, a new investigational drug originally developed for type 2 diabetes that is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease.
Credit: Video courtesy of the Patrik Brundin Laboratory, Van Andel Research Institute.
Copyright © 2019 Metabolic Solutions Development Company - All Rights Reserved.